This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In his review of ePocrates qRx Dr Hogan fails to discuss the pharmaceutical industry's access to ePocrates-assembled data on physician prescribing behavior.¹ While Hogan extols the convenient AutoUpdate feature, he neglects to mention that personally identifiable usage data are also uploaded to the ePocrates server during the same process.

The ePocrates privacy policy illustrates the usage data obtained: "This [sic] data may include, for instance, which Software screens you visit most often and the number of times you have looked up a certain drug."² These data may be sold to third parties, but, barring acquisition of ePocrates, Inc or its assets, pharmaceutical firms are only permitted to purchase aggregated data.² Even lacking access to user-specific information, however, pharmaceutical firms can learn much about physician prescribing behavior. The ePocrates data provide pharmaceutical firms with an additional tier of information not available previously: insights into the processes that . . . [Full Text of this Article]

RELATED ARTICLE

Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Ashley Wazana
JAMA. 2000;283(3):373-380.
ABSTRACT | FULL TEXT